Literature DB >> 22256762

[Effect of recombinant trichosanthin on proliferation of human cevical cancer Caski cells].

Pingping Peng1, Liming Huang, Yanlin Wang, Chengcheng You, Weihong Cao, Huamei Song, Hanxing Tan, Yanzhen Wu.   

Abstract

OBJECTIVE: To observe the effects of high expression of recombinant trichosanthin (rTCS) on the cell proliferation and cell cycle of human cervical cancer Caski cells.
METHOD: Eukaryotic expression plasmid pcDNA3.1(-)/6His-TCS was constracted and stably transfected into Caski cells. RT-PCR,Western-blot were used to select the clones with rTCS high-expressing. Using pcDNA3.1(-)-transfected cells as the control, MTT assay and flowcytometry were used to elucidate the effects of rTCS high expression on cell growth and cycle regulation in Caski cells. RESULT: The Caski cells with stable high expression of rTCS was successfully established, which could inhibit the cell growth (P<0.01) and arrest Caski cells in G1 and G2 phases (P<0.05) obviously.
CONCLUSION: High expression of rTCS can inhibit the growth of Caski cervical cancer cells, which might provide a new pathway for the therapy of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22256762

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  3 in total

Review 1.  Anti-tumor activities and apoptotic mechanism of ribosome-inactivating proteins.

Authors:  Meiqi Zeng; Manyin Zheng; Desheng Lu; Jun Wang; Wenqi Jiang; Ou Sha
Journal:  Chin J Cancer       Date:  2015-07-17

Review 2.  Structural and Functional Investigation and Pharmacological Mechanism of Trichosanthin, a Type 1 Ribosome-Inactivating Protein.

Authors:  Wei-Wei Shi; Kam-Bo Wong; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2018-08-20       Impact factor: 4.546

Review 3.  Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review.

Authors:  Ou Sha; Junfei Niu; Tzi-Bun Ng; Eric Yu-Pang Cho; Xiaoyuan Fu; Wenqi Jiang
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-03       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.